Protego Biopharma Inc. has identified prodrugs of transthyretin (TTR; PALB) stabilizers acting as TTR aggregation and/or amyloid formation inhibitors reported to be useful for the treatment of familial amyloid polyneuropathy and familial amyloid cardiomyopathy.